Ikena Stock Analysis

IKNA -  USA Stock  

USD 13.27  0.78  5.55%

The big decline in price over the last few months for Ikena Oncologymay raise some interest from investors. The stock closed today at a share price of 13.27 on 392,400 in trading volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Ikena Oncology or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.87. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Ikena Oncology partners.
Please see Risk vs Return Analysis.

Search Stock Analysis 

 
Refresh
The Ikena Oncology stock analysis report makes it easy to digest most publicly released information about Ikena Oncology and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ikena stock analysis module also helps to analyze the Ikena Oncology price relationship with some important fundamental indicators such as market cap and management efficiency.

Ikena Stock Analysis Notes

The company had not issued any dividends in recent years. Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. To learn more about Ikena Oncology call the company at 857-273-8343 or check out http://ikenaoncology.com.

Ikena Oncology Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ikena Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ikena Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ikena Oncology generates negative expected return over the last 90 days
Ikena Oncology has high historical volatility and very poor performance
Ikena Oncology has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 9.19 M. Net Loss for the year was (44.26 M) with loss before overhead, payroll, taxes, and interest of (24.51 M).
Ikena Oncology currently holds about 162.49 M in cash with (37.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.23.
Ikena Oncology has a frail financial position based on the latest SEC disclosures
Latest headline from www.equities.com: Ikena Oncology Inc falls -2.1850 percent for June 15 - Equities.com

Ikena Largest EPS Surprises

Earnings surprises can significantly impact Ikena Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-13
2021-03-31-0.68-2.52-1.84270 
View All Earnings Estimates

Ikena Oncology SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ikena Oncology prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ikena Oncology investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ikena Oncology specific information freely available to individual and institutional investors to make a timely investment decision.
13th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
15th of April 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
14th of April 2021
Unclassified Corporate Event
View
12th of April 2021
Unclassified Corporate Event
View
9th of April 2021
Unclassified Corporate Event
View
5th of April 2021
Unclassified Corporate Event
View
30th of March 2021
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Ikena Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ikena Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ikena Oncology backward and forwards among themselves. Ikena Oncology's institutional investor refers to the entity that pools money to purchase Ikena Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares3.8 M99.7 M
Orbimed Advisors LlcCommon Shares2.9 M82.9 M
Omega Fund Management LlcCommon Shares2.2 M63.5 M
Citadel Advisors LlcCommon Shares2.1 M58 M
Bvf IncCommon Shares1.6 M45.2 M
Artal Group SaCommon Shares1.5 M43.8 M
Farallon Capital Management LlcCommon Shares1.3 M38.1 M
Note, although Ikena Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ikena Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 977.11 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ikena Oncology's market, we take the total number of its shares issued and multiply it by Ikena Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ikena Profitablity

Ikena Oncology's profitability indicators refer to fundamental financial ratios that showcase Ikena Oncology's ability to generate income relative to its revenue or operating costs. If, let's say, Ikena Oncology is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ikena Oncology's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ikena Oncology's profitability requires more research than a typical breakdown of Ikena Oncology's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.31) (0.34) 
Return on Average Equity 0.49  0.49 
Return on Invested Capital 1.87  1.86 
Return on Sales(4.81) (5.19) 

Management Efficiency

The entity has return on total asset (ROA) of (16.4) % which means that it has lost $16.4 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (72.35) %, meaning that it created substantial loss on money invested by shareholders. Ikena Oncology management efficiency ratios could be used to measure how well ikena oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of June 19, 2021, Return on Average Assets is expected to decline to -0.34. In addition to that, Return on Invested Capital is expected to decline to 1.86. As of June 19, 2021, Total Assets is expected to decline to about 162.3 M. In addition to that, Current Assets is expected to decline to about 160.1 M
Last ReportedProjected for 2021
Book Value per Share(36.54) (39.43) 
Tangible Assets Book Value per Share 60.90  59.08 
Tangible Asset Value168.4 M162.3 M

Technical Drivers

As of the 19th of June, Ikena Oncology retains the market risk adjusted performance of 1.5, and Risk Adjusted Performance of (0.12). Ikena Oncology technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Ikena Oncology, which can be compared to its competitors. Please check out Ikena Oncology coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Ikena Oncology is priced fairly, providing market reflects its last-minute price of 13.27 per share. Given that Ikena Oncology has jensen alpha of (1.21), we strongly advise you to confirm Ikena Oncology's regular market performance to make sure the company can sustain itself at a future point.

Ikena Oncology Price Movement Analysis

The output start index for this execution was thirty-nine with a total number of output elements of twenty-one. Ikena Oncology Triple Exponential Moving Average indicator shows smoothing effect of Ikena Oncology price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average overlap studies indicator.

Ikena Oncology Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ikena Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ikena Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ikena Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ikena Oncology Predictive Daily Indicators

Ikena Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ikena Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ikena Oncology Forecast Models

Ikena Oncology time-series forecasting models is one of many Ikena Oncology's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ikena Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Ikena Oncology Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ikena Oncology stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ikena shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Ikena Oncology. By using and applying Ikena Stock analysis, traders can create a robust methodology for identifying Ikena entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(4.68) (5.05) 
Gross Margin 0.90  0.89 
Profit Margin(4.81) (5.19) 
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.

Current Ikena Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ikena analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ikena analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
27.0Strong Buy1Odds
Ikena Oncology current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ikena analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ikena stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ikena Oncology, talking to its executives and customers, or listening to Ikena conference calls.
Ikena Analyst Advice Details

Ikena Stock Analysis Indicators

Ikena Oncology stock analysis indicators help investors evaluate how Ikena Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ikena Oncology shares will generate the highest return on investment. By understating and applying Ikena Oncology stock analysis, traders can identify Ikena Oncology position entry and exit signals to maximize returns.
Quick Ratio5.74
Fifty Two Week Low19.01
Gross Margins-266.62%
Revenue Growth-97.70%
Float Shares11.57M
Fifty Two Week High37.61
Average Daily Volume Last 10 Day1.08M
Average Daily Volume In Three Month1.08M
Enterprise Value To Ebitda-18.71
Fifty Day Average28.63
Two Hundred Day Average28.63
Enterprise Value To Revenue67.33
Please see Risk vs Return Analysis. Note that the Ikena Oncology information on this page should be used as a complementary analysis to other Ikena Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Ikena Oncology Stock analysis

When running Ikena Oncology price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Ikena Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.